Brokerages Set argenx SE (NASDAQ:ARGX) PT at $662.83

argenx SE (NASDAQ:ARGX) has been assigned a consensus rating of “Moderate Buy” from the twenty-two analysts that are covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation, eighteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $687.00.

A number of equities research analysts have weighed in on ARGX shares. Wedbush reissued an “outperform” rating and issued a $655.00 target price on shares of argenx in a report on Tuesday, December 3rd. JMP Securities boosted their target price on argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a report on Tuesday, January 14th. Truist Financial reissued a “buy” rating and issued a $700.00 target price (up previously from $660.00) on shares of argenx in a report on Tuesday, January 14th. Guggenheim boosted their target price on argenx from $775.00 to $1,100.00 and gave the company a “buy” rating in a report on Monday. Finally, HC Wainwright boosted their target price on argenx from $717.00 to $720.00 and gave the company a “buy” rating in a report on Friday, February 28th.

Institutional Trading of argenx

Institutional investors and hedge funds have recently made changes to their positions in the stock. GeoWealth Management LLC lifted its position in shares of argenx by 56.3% in the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock valued at $31,000 after acquiring an additional 18 shares in the last quarter. Whipplewood Advisors LLC purchased a new stake in shares of argenx in the fourth quarter valued at $37,000. Global Retirement Partners LLC lifted its position in shares of argenx by 369.2% in the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock valued at $38,000 after acquiring an additional 48 shares in the last quarter. FIL Ltd purchased a new position in argenx during the fourth quarter worth about $38,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in argenx during the fourth quarter worth about $38,000. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenx Stock Performance

Shares of ARGX opened at $591.45 on Friday. The stock has a 50-day simple moving average of $639.78 and a 200-day simple moving average of $595.30. The stock has a market capitalization of $35.94 billion, a PE ratio of -672.10 and a beta of 0.59. argenx has a 1 year low of $349.86 and a 1 year high of $678.21.

argenx (NASDAQ:ARGX) last posted its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.60. The firm had revenue of $761.22 million during the quarter, compared to analysts’ expectations of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. Analysts predict that argenx will post 3.13 EPS for the current year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.